The Court remedied the constitutional infirmity by severing a portion of 35 U.S.C. § 6(c) that limited decisions on rehearing requests to the PTAB, i.e., the APJs. Id. at 1987 (severing part of 35 U.S.C. § 6(c) which provided that "[o]nly the Patent Trial and Appeal Board may grant rehearings.").
Put another way, as a result of Arthrex, decisions by the APJs are now reviewable by the USPTO Director, a principal officer. This remedy is different from that previously crafted by the U.S. Court of Appeals for the Federal Circuit and has additional implications for PTAB trial practice.
Excerpted from Reuters. To read the full article, click here.